Array BioPharma sends NDA for binimetinib to FDA
Array BioPharma recently announced that it has sent the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for its binimetinib treatment for patients who have advanced NRAS-mutant melanoma. Read More »